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Introduction
HIV-1 integrates into the host chromosome and persists
as a provirus flanked by long terminal repeats (LTR). To
date, treatment regimens primarily target the virus
enzymes, virus attachment or virus-cell fusion, but not
the integrated provirus. Thus, current antiretroviral
therapies (i.e. cART) cannot eradicate HIV-1, a fact that
highlights the urgency of pursuing new strategies to find
a cure for HIV/AIDS.
Previously, we engineered an experimental LTR-specific
recombinase (Tre-recombinase) that can effectively excise
integrated HIV-1 proviral DNA from infected human cell
cultures (Sarkar et al. 2007 Science 316:1912). Subse-
quently, we demonstrated highly significant antiviral activ-
ity of this HIV-1 subtype A-specific Tre in humanized
mice (Hauber et al. 2013 PLOS pathogens 9:e1003587).
Broad clinical application, however, requires availability of
a tre-recombinase that recognizes a majority of clinical
HIV-1 isolates.
Materials and methods
Here we report LTR target site identification as well as the
engineering and functional analysis of a next-generation
Tre-recombinase that recognizes the vast majority (e.g.
>93% clade B and >80% clade A) of clinical HIV-1 isolates.
Results
It is shown that the HIV-1 LTR harbours a conserved
region that may serve as a universal tre recognition site
for provirus excision. In fact, targeting this site by next-
generation tre-recombinase demonstrates pronounced
antiviral activity in the absence of cellular toxicity.
Conclusion
The presented data suggest that next-generation Tre tech-
nology may be a valuable component of future antiretro-
viral therapies to reverse infection and thereby providing a
cure for HIV/AIDS.
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